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Introduction
§ Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis 
is an autoimmune disorder that was only recently 
discovered through the identification of the anti-NMDAR 
autoantibody in 2007 (Brenton, Schwartz & Madoo, 2015, p. 
14).
§ With an increasing amount of new cases of this 
autoimmune disorder on the rise, it is important for 
healthcare providers to be aware of its pathophysiology, 
presentation, course of disease, and treatment modalities 
for the successful management of patient’s with anti-
NMDAR encephalitis.
Signs & Symptoms
§ Various stages of the anti-NMDAR encephalitis disease course, 
with the initial stage being the prodromal phase, which typically 
lasts a few days to a few weeks. The prodromal symptoms 
typically include those involving the upper respiratory and GI 
tracts (nausea and vomiting), low grade fevers, and headaches.
§ Several weeks later, new symptoms start to appear, such as 
behavioral changes that include irritability, various psychiatric 
symptoms, memory disturbances, speech disorders, seizures, 
dyskinesia, ↓  LOC, autonomic instability, and hypoventilation. 
The late stages of this disease almost always require ICU 
management (Brenton, 2015, pp. 15-16).
§ In children, the initial symptoms tend to include more 
behavioral in nature, such as temper tantrums, hyperactivity, 
seizures, motor abnormalities, and irritability. Autonomic 
instability and hypoventilation tend to be more prevalent in 
adults than in children with anti-NMDAR encephalitis (Varma & 
Sapra, 2015, p. 574). 
§ Cardiac dysrhythmias have also been seen in anti-NMDAR 
patients (Park, Mittal, Lala & Patel, 2016, p. 35). Because of the 
diverse amount of symptoms in the initial stages of this 
disorder, missed diagnosis is not uncommon (Hong et al., 2015, 
p. 3). 
Figure 1. Anti-NMDA disease course (Rare Disease Review, 2017)
Pathophysiology & its Significance
§ NMDA receptors are neuronal ECF receptors in the brain that play a 
role in memory, behavior, and learning. Tumors  (ovarian) appear to 
regulate the production of anti-NMDAR antibodies within the tumor 
tissue and the intrathecal areas of the brain. The IgG subclass, G1 
autoantibodies, bind to the NR1 subunit of the NMDA receptors, 
causing significant (but reversible) loss of NMDA receptors in the brain 
(Brenton et al., 2015, p. 15). 
§ According to Hong, Klein-Gitelman &Wainwright (2015), a herpes 
simplex virus infection is emerging as another potential trigger for anti-
NMDAR encephalitis (p.4).
§ The hyperactivity of NMDA receptors can lead to neurotoxicity, and is 
possibly linked to the pathophysiology of acute brain injuries. When 
there is a sustained hypo-functioning of the NMDA receptors, it can 
lead to subsequent cognitive dysfunction, and is thought to be 
involved in the pathophysiology of psychosis, Alzheimer’s disease, and 
autoimmune encephalitis (Varma & Sapra, 2015, p. 572). 
§ Once the IgG antibodies bind to the NMDARs, there is a reversible 
internalization of the receptors from both the synaptic and extra 
synaptic space. The number of synapses, dendritic structure, and cell 
survival are not affected. The loss of the NMDARs on the cellular 
surface then correlates with the antibody titers, which are discussed 
later. The NMDARs are affected on both excitatory and inhibitory 
neurons, and it is the internalization of these receptors that result in 
the behavioral and neurological changes seen within the course of this 
disease (Kayser & Dalmau, 2016, p. 37).
§ The ↓ in the NMDARs on cellular surfaces results in ↓ functioning of 
the NMDA-receptor system, which in addition to causing anti-NMDAR 
encephalitis, is often associated with schizophrenia (van de Riet, 
Esseveld, Cuypers, & Schieveld, 2013, p. 319).
§ Up to 80% of those afflicted by anti-NMDAR encephalitis are female, 
but it is becoming increasingly recognized in both genders across the 
entire lifespan, from one year old, to 90 year olds, with the median age 
being 21 years old (Varma & Sapra , 2015, p. 574).
§ 40% of those diagnosed with anti-NMDAR are less than 18 years old 
(Brenton et al., 2015, p. 15).
§ The presence of teratomas and other underlying tumors is dependent 
on the patient’s age and sex. Children under 12 years old, and male 
patients, rarely have a tumor (Kayser & Dalmau, 2016, p. 36).
§ Diagnosis involves a combination of MRI, which has shown 
abnormalities in 50% of the patients; EEG, which is abnormal in 
most cases, and CSF analysis, which is abnormal in most patients. 
Abnormalities in the CSF include a ↑ WBC count, and presence of 
CSF-specific oligoconal bands in 60% of the patients (Marsland & 
Bray, 2012, p. 277). 
§ Gold standard for diagnosis is the identification of antibodies to 
the NR1 subunit of the NMDAR, with evaluation of the CSF being 
more sensitive than serum, but evaluation of both is 
recommended (Hong et al., 2015, p. 4).
Nursing Implications
§ The prompt diagnosis and treatment of anti-NMDAR 
encephalitis has been shown to significantly ↓ the morbidity 
and mortality, and ↓ the risk of irreversible neuronal damage
§ Treatment includes various modalities, with the primary 
emphasis being on the surgical removal of the associated 
tumor/malignancy, along with immunosuppression therapy, 
such as with the use of corticosteroids, IVIg, plasmapheresis, 
rituximab, cyclophosphamide, and azathioprine (Gulyayeva, 
Massie & Duhamel, 2014, pp. 162-163).
§ Specialized psychiatric care is needed to treat & manage the 
severe neuropsychiatric symptoms associated with this disease 
(van de Riet, 2012, p. 322).
§ Nursing care of the anti-NMDAR encephalitis patient can be  
very challenging due to the acute confusion/encephalitis..
§ Nursing care can be divided into 3 stages: the acute phase, the 
rehabilitation phase, and the discharge phase. During the acute 
phase, nursing responsibilities include: frequent observations 
to monitor for clinical deterioration and seizures, frequent 
neuro assessments, assisting with LPs, clustering of care, 
monitoring fluid balance, and administering meds frequently 
and promptly. During the rehab phase, nurses should ensure 
patient understands discharge plan, consider a referral to 
psychological services for familial support, and participate in 
the multidisciplinary meetings with patient and family. During 
the discharge phase, it is important for the nurse to: provide 
support to patient and their family, provide information on 
encephalitis to patient, including various support groups, start 
the discharge planning as soon as possible, consider referral to 
mental health services if depression is suspected, and ensure 
patient has appropriate follow up visits scheduled (Matata et 
al., 2015, pp. 52-53).
Figure 2. Anti-NMDA receptor (Euroimmun US, 2017).
Conclusion
Anti-NMDAR encephalitis is going to be seen more often in 
the years to come, and therefore it is imperative that the 
APN is familiar with its pathophysiology, signs and 
symptoms, disease course, and treatment options available. 
The patient outcomes with anti-NMDAR encephalitis 
improve exponentially when quick identification of the 
disease leads to prompt initiation of the various treatment 
modalities. The APN, in the many various areas of 
healthcare, can assist in the successful outcomes for patients 
with anti-NMDAR encephalitis through their knowledge on 
this complicated disease. 
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